INTRODUCTION
Hypoalbuminemia occurs frequently during the early post-renal transplantation period in renal transplant recipients. Hypoalbuminemia, followed by low intravascular volume, delays the onset of urine output, decreases urine volume, delays recovery of renal function, and increases the rate of delayed graft function [1] . Patients undergoing various surgical procedures show transient hypoalbuminemia that occurs during the early post-operative period (usually within the first week) [2, 3] . In contrast, we have experienced long-lasting, noticeable hypoalbuminemia, often associated with decreased urine output, slowly recovering or even worsening renal function that was initially recovering, and ascites formation in renal transplant recipients during the early post-operative period.
In a retrospective analysis of 200 renal transplant recipients at our center, serum albumin levels decreased by more than 0.5 g/dL in 44% of recipients during the first month after the operation. The lowest serum albumin levels were observed at post-operative day 14, which recovered to pre-operative levels at 60 days after the operation. We have also observed that an albumin infusion recovers urine output and renal function very quickly in cases of hypoalbuminemia-induced renal dysfunction.
Hypoalbuminemia generally results from decreased hepatic synthesis, increased catabolism, protein loss from the intravascular space, or plasma dilution. Protein loss could not explain the hypoalbuminemia in our transplant recipients, because most of our recipients were orally fed for 2 days, and losses in wound drainage were minimal. We found no correlation between changes in serum albumin levels and changes in body weight, indicating that plasma dilution was not the cause for the hypoalbuminemia.
High-dose cyclosporin A (CsA) is routinely administered to renal transplant recipients during the early postoperative period, and this drug is well known to be hepatotoxic and to regulate hepatic enzymes including cytochrome P450. CsA inhibits hepatic protein synthesis, probably at the translation level, based on in vitro and in vivo experiments [4] [5] [6] . However, it has not been clearly determined if CsA regulates hepatic albumin synthesis.
In this study, we examined albumin gene expression in 
METHODS

Cell culture
Huh7 cells, a human hepatoma cell line, were maintained in Modified Eagle's medium (MEM) supplemented with 10% heat inactivated fetal bovine serum and an antibiotic/antifungal solution. Cell cultures were maintained at 37°C under 5% CO 2 . All cell culture materials were purchased from Gibco BRL (Gaithersburg, MD, USA).
Enzyme-linked immunosorbent assay
Albumin in the conditioned medium released from 
Western blot analysis
Confluent Huh7 cells, plated in six-well dishes, were 
RNA Isolation and Northern blot analysis
Statistical analysis
Statistical comparisons between multiple groups were performed with an analysis of variance, and Bonferroni's method was applied to control for multiple testing. A p value < 0.05 was considered statistically significant. CsA inhibited albumin synthesis by 48%, 60% and 82% at concentrations of 10 -6 M, 10 -5 M, and 10 -4 M, respectively (Fig. 1A) . The inhibition of albumin synthesis by CsA was statistically significant at 24 hours (Fig. 1B) . A Western blot analysis for albumin in the conditioned medium released from Huh7 cells also revealed that CsA inhibited albumin synthesis in a dose-dependent manner at doses from 10 -7 M to 10 -5 M, whereas the vehicle did not (Fig. 1C) .
RESULTS
Albumin synthesis in Huh7 cells
Cell viability
Cell viability was tested by staining the cells from each 
Albumin gene expression
The Northern blot analysis revealed that CsA (10 hours between untreated and CsA-treated Huh7 cells, indicating that inhibition of albumin synthesis by CsA occurred at the translational level (Fig. 2B ).
DISCUSSION
The principal finding of this study was that CsA inhibited translation of albumin synthesis in Huh7 cells. A special synthetic assembly line for the synthesis of proteins for export, including serum albumin, is present within hepatocytes. After DNA-directed specific RNA synthesis, the protein production process proceeds in the cytoplasm.
The ribosome consists of two subunits, a smaller unit (40-S) and a larger unit (60-S). The smaller subunit is attached to mRNA, whereas the larger subunit is attached to the microtubular structure, the endoplasmic reticulum. As the albumin molecule is synthesized, it is inserted through the center of the larger subunit into the endoplasmic reticulum, and is then extruded into the hepatic plasma by traversing both the smooth endoplasmic reticulum and Golgi apparatus [7] [8] [9] .
Huh7 cells have been used for biological assays and are known to secrete many endogenous proteins, including α-fetoprotein, β2-microgloblin, integrins and transferring [10] [11] [12] [13] . Confluent Huh7 cells secreted a large amount of albumin, which accumulated continuously up to 48 hours.
Our finding of a decreased amount of albumin in the con- CsA is hepatotoxic including inhibition of hepatic protein synthesis. CsA administered orally (100 mg/kg/day) to rats for 21 days causes marked decreases in total serum protein and albumin, accompanied by rises in alkaline phosphatase and total bilirubin. A morphological examination of the liver revealed moderate centrilobular fatty changes and minor dilatation of endoplasmic reticulum [14] . In our experiments, more than 95% of Huh7 cells treated with CsA were viable. Inhibition of hepatic We also measured transferrin in the conditioned medium by direct ELISA, which is a protein typically produced in the liver. CsA significantly inhibited transferrin synthesis at 10 -7 M and higher doses in a dosedependent manner (data not shown). It is likely that CsA inhibits not only albumin synthesis but also synthesis of other proteins produced in the liver. A previous study
showed that both albumin and transferrin levels were reduced in the supernatant treated with CsA [15] . Albumin and transferrin are negative acute-phase proteins that are excellent markers of mortality risk in patients with endstage renal disease [16, 17] and may contribute to mortality after kidney transplantation.
In many transplant centers, including ours, the CsA whole-blood trough level target during early renal transplantation period is approximately 400 ng/mL, which accounts for 3 × 10 -7 M. In an animal study, CsA concentration in liver tissue was 9.5 times higher than that in blood [18] . Therefore, when the whole-blood trough level is 3 × 10 -7 M, the concentration in liver tissue may approach 2.85 × 10 -6 M. Furthermore, peak levels of CsA in blood are five times higher than trough levels. In this study, CsA significantly inhibited albumin synthesis in Huh7 cells at 10 -6 M or higher concentrations, which could be the liver tissue exposure level in transplant recipients.
In all patients with post-transplant hypoalbuminemia, serum albumin levels increase gradually as CsA dose is serially reduced. This clinical finding seems to be associated with the observation that CsA-induced hepatotoxicity, including hypoalbuminemia, improves when CsA concentration in liver tissue is < 10 -6 M.
Several studies have reported on the effect of tacrolimus (FK-506) and CsA on albumin secretion. In one study, FK-506 did not influence albumin secretion, but CsA mildly inhibited albumin production in HepG2 cells. That study also showed that FK-506 but not CsA attenuated the inhibitory effect of interleukin-6 on albumin secretion [19] . Another study comparing a different effect of CsA and FK-506 on hepatic albumin secretion revealed that albumin and transferrin production in CsA-treated cells decreased significantly compared to that in solvent or FK-506-treated cells [15] . Although CsA and FK-506 share the same mechanism of action in downregulating cytokines by inhibiting calcineurin, we assume that the inhibitory effect of CsA on albumin hepatic synthesis may not be through calcineurin inhibition. The mechanisms and sites of albumin degradation have not been identified yet. The kidney has been shown not to play a significant role in albumin degradation in the normal state, but may play an active role in disease states. In a rat model of nephrotic syndrome, a bilateral nephrectomy decreases the absolute albumin catabolic rate by about 50%. In the normal condition, small amounts of albumin, which traverse the glomerular filter, are catabolized by tubular cells. Electron microscopy has revealed albumin transport across the convoluted and proximal straight segments of the tubule [20] [21] [22] . However, it must be determined if albumin catabolism in the kidney increases following the administration of immunosuppressive agents or by transplantation surgery itself.
In conclusion, our results provide evidence that highdose CsA inhibits hepatic albumin synthesis at the level of translation, which is a mechanism for CsA-induced hepatotoxicity and might be a cause of hypoalbuminemia in renal transplant recipients during the early posttransplantation period. CsA-induced hypoalbuminemia needs to be included in the differential diagnosis of early acute renal dysfunction in renal transplant recipients.
